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Unaltered intravenous prion 
disease pathogenesis in the 
temporary absence of marginal 
zone B cells
Barry M. Bradford  & neil A. Mabbott  *
Prion diseases are a unique, infectious, neurodegenerative disorders that can affect animals and 
humans. Data from mouse transmissions show that efficient infection of the host after intravenous (IV) 
prion exposure is dependent upon the early accumulation and amplification of the prions on stromal 
follicular dendritic cells (FDC) in the B cell follicles. How infectious prions are initially conveyed from the 
blood-stream to the fDc in the spleen is uncertain. Addressing this issue is important as susceptibility 
to peripheral prion infections can be reduced by treatments that prevent the early accumulation of 
prions upon FDC. The marginal zone (MZ) in the spleen contains specialized subsets of B cells and 
macrophages that are positioned to continuously monitor the blood-stream and remove pathogens, 
toxins and apoptotic cells. The continual shuttling of MZ B cells between the MZ and the B-cell follicle 
enables them to efficiently capture and deliver blood-borne antigens and antigen-containing immune 
complexes to splenic FDC. We tested the hypothesis that MZ B cells also play a role in the initial 
shuttling of prions from the blood-stream to FDC. MZ B cells were temporarily depleted from the MZ 
by antibody-mediated blocking of integrin function. We show that depletion of MZ B cells around the 
time of IV prion exposure did not affect the early accumulation of blood-borne prions upon splenic FDC 
or reduce susceptibility to IV prion infection. In conclusion, our data suggest that the initial delivery of 
blood-borne prions to FDC in the spleen occurs independently of MZ B cells.
Prion diseases (also known as transmissible spongiform encephalopathies) are unique, infectious, invariable fatal, 
neurodegenerative diseases. Infectious prion particles appear to be comprised almost entirely of PrPSc (misfolded 
forms of the host’s cellular prion protein, PrPC)1 suggesting that prions are infectious proteins2,3. The accumula-
tion of PrPSc in the brain during prion disease coincides with extensive astrocytic and microglial activation and 
ultimately leads to neurodegeneration coincident with a spongiform (sponge-like) pathology (vacuolation) in 
the brain.
Infection with some natural prion diseases including natural sheep scrapie and chronic wasting disease in 
cervids occurs after peripheral exposure to infectious prions, for example by oral ingestion of food or pasture con-
taminated with prions. Bovine spongiform encephalopathy in cattle can be zoonotic, as the consumption of con-
taminated food in the UK led to the emergence of a novel human prion strain known as variant Creutzfeldt-Jakob 
disease (vCJD). After peripheral infection some prion agent strains accumulate and replicate first upon stromal 
follicular dendritic cells (FDC) in the B-cell follicles of host’s secondary lymphoid tissues including the Peyer’s 
patches, lymph nodes and spleen (reviewed in4). After their amplification within these tissues the prions then 
infect the sympathetic and parasympathetic nervous systems in order to establish CNS infection5–8. Studies in 
mice suggest that after peripheral exposure the initial replication of certain prion agents within the host’s second-
ary lymphoid tissues is important to efficiently establish CNS infection5,6,9–12.
The marginal zone (MZ) in the spleen provides a border around the lymphocyte-containing white pulp 
region and contains a marginal sinus through which the peripheral blood percolates as it travels towards the 
red pulp13. Specialized subsets of B cells and macrophages are positioned within the MZ to continuously mon-
itor the blood-stream and remove pathogens, toxins and apoptotic cells. The MZ B cells, for example, capture 
blood-borne antigens and antigen-containing immune complexes13–16. By continually shuttling between the MZ 
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and the B-cell follicle these cells efficiently capture and deliver systemic antigens and antigen-containing immune 
complexes to the FDC in the B cell follicles14,15. The innate-like characteristics of the MZ B cells also enable them 
to initiate rapid T-cell-independent antibody responses to certain polysaccharide antigens such as those from 
encapsulated bacteria17,18.
In the UK a small number of accidental iatrogenic cases of the human prion disease vCJD have been described 
in patients that received blood or blood products prepared from donors infected with vCJD prions4,19–21. After 
intravenous (IV) injection with prions their early amplification upon splenic FDC is also essential for efficient 
disease pathogenesis12. However, little is known of the cellular and molecular processes that mediate the initial 
propagation of blood-borne prions towards the FDC within the spleen. Prions can be captured and acquired 
by FDC as prion-containing complement component-opsonized complexes22–27. Furthermore, aged mice have 
a significantly reduced susceptibility to IV prion injection, and this coincides with disturbances to the cellular 
organization within the MZ that impede the transport of antigen-containing immune complexes and prions to 
FDC12. Therefore, since MZ B cells capture and deliver blood-derived antigens and antigen-containing immune 
complexes to splenic FDC, we tested the hypothesis that MZ B cells similarly shuttle blood-borne prions towards 
FDC12. Specifically, we determined whether the depletion of MZ B cells from the MZ niche by blocking integrin 
function28 would impede the initial delivery of prions from the blood-stream to FDC, and by doing so, reduce 
susceptibility to IV prion infection.
Results
Treatment with anti-LFA-1 and anti-α4 displaces MZ B cells from the splenic MZ. Mouse MZ B 
cells express the integrins LFA-1 (lymphocyte function-associated antigen 1; αLβ2) and α4β1 highly and this ena-
bles them to bind to the adhesion molecules ICAM-1 (intracellular adhesion molecule 1) and VCAM-1 (vascular 
cell adhesion molecule 1) that are expressed in the MZ by the marginal sinus lining cells28. Antibody-mediated 
inhibition of this binding rapidly releases and displaces the MZ B cells from the MZ28. Here, the temporary dis-
placement of MZ B cells from the splenic MZ was achieved as described previously28–30 by IV treatment of mice 
with anti-αL and anti-α4 monoclonal antibodies (mAb) to specifically inhibit the LFA-1 (αLβ2) and α4β1 integ-
rins (termed anti-αL + anti-α4, herein after). Some mice were injected IV with non-specific Ig isotype-matched 
antibodies as a control (control-Ig). Spleens were analysed 7 days after treatment. Within the splenic B lympho-
cyte compartment mouse MZ B cells can be identified by flow cytometry as B220 + CD21hiCD1dhi cells13,28. Here, 
flow cytometry confirmed that anti-αL + anti-α4 treatment led to a highly significant reduction in the abundance 
of MZ B cells in the spleen (Fig. 1A,B).
By immunohistochemistry (IHC) MZ B cells can be readily identified within the splenic MZ based on 
their high expression of IgM and low expression of IgD, or their high expression of CD1d12,28 (Fig. 1C,D). 
Our IHC analysis confirmed an almost complete absence of IgM + and CD1d + MZ B cells from the MZ of 
anti-αL + anti-α4 treated mice (Fig. 1C,D). Together these data confirm that MZ B cells are displaced from the 
splenic MZ by treatment with anti-αL + anti α4 mAb.
The MZ also contains specialized populations of macrophages that are situated within two separate continu-
ous layers on either side of the marginal sinus. The MZ macrophages form a ring within the outer layer of the MZ 
and express the macrophage receptor with collagenous structure (MARCO) scavenger receptor. Some of these 
MZ macrophages also express the C-type lectin specific intracellular adhesion molecule-grabbing non-integrin 
receptor 1 (SIGNR1). The inner layer of MZ metallophilic macrophages express CD169 (siglec-acid-binding 
immunoglobulin-like lectin 1; SIGLEC1; Fig. 1E, upper panels). Our IHC analysis indicated that the distribution 
of these macrophage populations was not affected in the spleens of anti-αL + anti-α4 treated mice (Fig. 1E, lower 
panels), in agreement with previously published data28.
Temporary displacement of MZ B cells does not affect the early accumulation of PrPSc in the 
spleen. Next, we assessed whether the depletion of MZ B cells would affect the early accumulation of prions 
upon splenic FDC after IV exposure. Mice were injected with anti-αL + anti-α4 mAb (or control-Ig) as above, 
and seven days layer injected IV with a low (0.1%) dose of ME7 scrapie prions. As anticipated, by 35 days after IV 
injection with prions, heavy prion disease-specific PrP (PrPd) accumulations were detected by IHC in association 
with FDC in the spleens of control-Ig treated mice (Fig. 2A). Paraffin-embedded tissue immunoblot analysis 
demonstrated the presence of prion disease-specific, relatively proteinase-resistant, PrPSc (Fig. 2B). The abun-
dance of these FDC-associated PrPSc accumulations in the spleens of control-Ig treated mice had increased by 
70 and 105 days after infection (Fig. 2C). Spleens from spleens anti-αL + anti-α4 treated mice also contained a 
similar abundance of PrPSc + FDC networks (Fig. 2A–C), suggesting that the absence of MZ B cells from the MZ 
at the time of IV prion injection did not impede the early accumulation of prions within the spleen.
Temporary displacement of MZ B cells does not affect susceptibility to IV prion infection. We 
next determined whether MZ B-cell displacement would affect susceptibility to IV prion infection. As above, 
groups of mice were treated with anti αL + anti-α4 mAb (or control-Ig) and seven days layer injected IV 
with a low dose of prions. All the prion injected control-Ig treated mice developed clinical prion disease with 
a mean survival time of 263 ± 11 days (median = 261 days, n = 7). Furthermore, all the prion injected anti 
αL + anti-α4 treated mice also developed clinical prion disease with similar survival times (mean = 269 ± 11 
days, median = 266 days, n = 8). The characteristic neuropathological signs of prion disease including spongi-
form pathology (vacuolation), PrPd accumulations, microglial activation (AIF-1 + cells) and reactive astrocytosis 
(GFAP + cells) were detected in the brains of all the clinically-affected mice from each group (Fig. 3A,B). The 
distribution and magnitude of the vacuolation was also similar in the brains from each treatment group (Fig. 3C). 
Together, our data suggest that the displacement of MZ B cells from the splenic MZ does not affect susceptibility 
to IV prion infection.
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Figure 1. Displacement of MZ B cells from the splenic MZ by antibody-mediated blockade of the integrins 
LFA-1 (αLβ2) and α4β1. Mice were treated with anti-αL and anti-α4 mAb (anti-αL + anti-α4), or isotype-
matched control-Ig (n = 4 mice/group), and spleens analysed seven days later. (A) Gating strategy used 
to identify B220 + CD21hiCD1dhi MZ B cells by flow cytometry. (B) The percentage of B cells that were 
B220 + CD21hiCD1dhi MZ B cells was significantly reduced in the spleens of anti-αL + anti-α4 treated mice. 
***P < 0.001, Student’s t-test; n = 4 mice/group; closed circles, control-Ig; open circles, anti-αL + anti-α4; 
horizontal bars, median. (C) Representative immunostaining of IgM + (violet) and IgD + (green) cells in the 
spleens of mice from each treatment group. This analysis showed that IgM + MZ B cells were absent from the 
MZ region of the spleens of anti-αL + anti-α4 treated mice. MZ, marginal zone; F, B-cell follicle; broken line 
shows the boundary of the MZ; scale bar, 100 µm. (D) Representative immunostaining of CD1d + (brown) 
cells in the spleens of mice from each treatment group. Haematoxylin (blue) was used as a nuclear 
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Discussion
The MZ B cells express the integrins LFA-1 (αLβ2) and α4β1 highly and this enables them to be retained within 
the MZ through their ability to bind to the adhesion molecules ICAM-1 and VCAM-1 expressed on surfaces of 
the sinus lining cells28. When the MZ B cells are activated their expression of these integrins is down-regulated28, 
releasing them from the marginal sinus and enabling their migration into the B-cell follicle towards gradients of 
the chemokine CXCL13 that is synthesised by FDC and follicular stromal cells15. The FDC express much higher 
levels of complement receptors CR2/CR1 (CD21/CD35) than the surrounding B cells and this allows the FDC to 
strip the complement-opsonised antigens and antigen-containing immune complexes from the B cells31. When 
the MZ B cells enter the B-cell follicles their expression of the chemokine receptor CXCR5 (the receptor for 
CXCL13) is down-regulated, but they upregulate their expression of the sphingosine-1-phosphate (S1P) recep-
tors14 S1P1 and S1P3. The blood in the marginal sinus has a relatively higher concentration of S1P when compared 
to the B-cell follicle, and this attracts the cells back to the MZ14. Since the MZ B cells continually shuttle between 
the MZ and B-cell follicles this provides an efficient route by which blood-borne antigens and antigen-containing 
immune complexes are delivered to splenic FDC14,15. We tested the hypothesis that MZ B cells also play mediate 
the initial shuttling of prions from the blood-stream to FDC. Treatment with blocking mAb against the integrins 
LFA-1 and α4β1 displaces the MZ B cells from the splenic marginal zone28, and has been used to study the role 
of these cells in host defence following infection with spirochete bacteria of the genus Borrelia29,30 and the intra-
cellular parasite Leishmania donovani32. The effects of anti-αL + anti-α4 treatment on MZ B cells are transient 
and result in their depletion for approximately 2-3 weeks during which time the MZ is repopulated with new cells 
from the bone marrow28,30. We therefore tested the hypothesis that depletion of MZ B cells from the MZ niche by 
blocking integrin function28 would impede the initial shuttling of prions from the blood-stream to splenic FDC, 
and by doing so, impair IV prion disease pathogenesis. However, data in the current study demonstrate that the 
early accumulation of prions upon splenic FDC and susceptibility to IV prion infection were both unaltered in 
anti-αL + anti-α4 treated mice. This suggests that the initial propagation blood-borne prions to FDC occurs 
independently of MZ B cells. Of course, although the mice in this study were injected IV with a low dose of pri-
ons (20 µl of 0.1% brain homogenate), we cannot rule out the possibility that MZ B cells may play a role in prion 
disease pathogenesis following IV exposure to very low doses of prions.
Since the period of MZ B cells displacement in the current study was transient (approximately 2–3 weeks) it is 
possible that the eventual repopulation of the MZ with MZ B cells restored the propagation of the IV injected prions 
towards FDC. However, data from independent studies would suggest this is unlikely to be a major factor. For exam-
ple, temporary blockade of tumour necrosis factor receptor 1 (TNFR1) signaling transiently de-differentiates the 
FDC in the spleen for approximately 1–2 weeks. Although the duration of the effects of TNFR1-blockade on FDC 
status were short and transient, this treatment reduced the early accumulation of prions in the spleen and signifi-
cantly increased survival times after peripheral exposure33. In the absence of early prion accumulation upon FDC it 
is likely that much of the injected inoculum is engulfed and destroyed by macrophages in the spleen11.
Other cell populations may help mediate the initial propagation of blood-borne prions to splenic FDC. The MZ 
metallophilic macrophages specifically express sialoadhesin (CD169), but although prion-specific PrPSc particles 
in the spleens of infected mice are highly sialylated34, deficiency in sialoadhesin (CD169/SIGLEC1) does not affect 
prion accumulation upon splenic FDC or disease susceptibility35. The expression of SIGNR1 by MZ macrophages 
acts as an uptake receptor for dextran, capsular pneumococcal polysaccharides and certain complement-opsonized 
antigens. However, the temporary down-regulation of SIGNR1 expression in MZ macrophages also does not 
affect prion disease pathogenesis after IV exposure36. Specific populations of conventional dendritic cells (cDC; 
antigen-presenting bone marrow-derived mononuclear phagocytes and a distinct lineage from the stromal 
FDC37,38) are positioned within the MZ bridging channels in the spleen, and can rapidly capture blood-borne par-
ticulate antigens39. An absence of cDC around the time of intra-peritoneal prion exposure impedes the early accu-
mulation of prions upon splenic FDC40,41. Furthermore, specific deficiency in CXCR5 expression in cDC restricts 
these cells from the B-cell follicles where the FDC reside and impedes the efficient propagation of prions towards 
FDC42. Thus, the cDC may instead mediate the early propagation of blood-borne prions to FDC in the spleen.
Our data do not exclude the possibility that blood-borne prions may also reach the FDC as cell-free 
complement-opsonised immune complexes22–27,43. For example, using fluorescently-labelled PrPSc fibrils Michele 
and colleagues suggested that small prion aggregates initially reach the draining lymph node by travelling through 
the afferent lymphatics in a passive cell-free manner43. A conduit system comprising a specialised network of 
stromal cells has been identified in the spleen that enables small blood-borne molecules (approx. ≤70 kDa) to be 
distributed throughout the white pulp44. A specific conduit system has also been described that forms a physical 
connection between the MZ and FDC within the B cell follicles45. Whether blood-borne monomers or dimers of 
prion-specific PrPSc are also passively delivered to FDC via the splenic conduit system or other route in sufficient 
magnitude to establish host infection remains to be determined.
The integrins αLβ2 (LFA-1) and α4β1 may also be expressed by other immune cell subsets. However, our IHC 
analysis suggested that αL + anti-α4 mAb treatment did not affect the abundance and distribution of follicular B cells 
(IgD-hi cells), MZ macrophages and marginal metallophilic macrophages in the spleen. Although this treatment can 
affect T cell-activation30, peripheral prion disease pathogenesis is not affected in mice deficient in T cells46–48.
counterstain. This analysis showed that CD1d + MZ B cells were absent from the MZ region of the spleens of 
anti-αL + anti-α4 treated mice. WP, white pulp region; broken line shows the boundary of the MZ; scale bar, 
500 µm. (E) Representative immunostaining shows a similar distribution of MARCO + (left-hand column), 
SIGNR1 + (middle column) and CD169 + (right-hand column) macrophages in the spleens of mice from each 
treatment group. Broken line shows the relative positioning of the marginal zinus. Scale bar, 100 µm.
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Figure 2. Temporary displacement of MZ B cells does not affect the early accumulation of PrPSc upon FDC in 
the spleen. Mice were treated with anti-αL and anti-α4 mAb (anti-αL + anti-α4), or isotype-matched control-Ig 
(n = 4 mice/group), and seven days later injected IV with ME7 scrapie prions. Spleens were analysed at 35, 70 
and 105 days after IV prion exposure. (A) Immunohistohemical (IHC) analysis shows heavy prion disease-
specific PrPd accumulations (upper row) were detected in association with FDC (CD21/CD35 + cells, arrows; 
middle row) in the B cell follicles (B220 + cells, bottom row) of mice from each treatment group. Haematoxylin 
(blue) was used as a nuclear counterstain. Scale bar, 100 µm. (B) Paraffin-embedded tissue immunoblotting was 
used to confirmed the presence of prion-specific, relatively PK-resistant, PrPSc (blue/black, arrows). Scale bar, 
100 µm. (C) Similar frequencies of PrPSc + FDC were detected in the spleens of mice from each treatment group. 
Closed circles, control-Ig; open circles, anti-αL + anti-α4; horizontal bars, median. n = 4 mice/group.
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The susceptibility of aged mice (~600 days old) to peripheral prion infection is dramatically reduced in con-
trast to young mice (~42–56 days old) and coincides with ageing-related disturbances to the microarchitecture 
of the secondary lymphoid tissues that impede the ability of FDC to efficiently acquire and replicate prions12,49–51. 
Specifically in the aged spleen the positioning and density of marginal sinus lining cells, MZ macrophages, 
MZ metallophilic macrophages and MZ B cells are each grossly disturbed12,13,49,52,53. As a consequence of these 
ageing-related disturbances to the MZ the propagation of blood-borne antigen-containing immune complexes 
and prions to FDC is adversely affected12,13. However, in the current study we show MZ B cell depletion did not 
affect the early accumulation of prions upon FDC. This suggest that the effects of ageing on prion accumulation 
upon FDC12 were also unlikely to be due to the effects of ageing on MZ B cells13. The expression of cellular PrPC 
in FDC is essential for them to be able to replicate prions11. Since PrPC expression in FDC is substantially reduced 
in aged mice this will significantly impact on their ability to replicate prions12,49. Whether ageing-related distur-
bances and thickening of the MZ13 adversely affect the blood flow through marginal sinus, reducing the shuttling 
of immune-complexes and prions to FDC, remains to be determined.
Further studies are necessary to determine how blood-borne prions establish infection upon splenic FDC. 
Treatments that impede the initial amplification of prions upon FDC can reduce susceptibility to peripherally-acquired 
Figure 3. Temporary displacement of MZ B cells does not affect CNS prion disease pathogenesis. Mice were 
treated with anti-αL and anti-α4 mAb (anti-αL + anti-α4), or isotype-matched control-Ig, and seven days later 
injected IV with ME7 scrapie prions (n = 7-8 mice/group). Brains were collected at the terminal stage of clinical 
prion disease and the neuropathology compared. (A) Immunohistopathological analysis shows abundant 
spongiform pathology (H&E, upper row), PrPd (brown, second row), AIF-1 + microglia (brown, third row) 
and GFAP + reactive astrocytes (brown, bottom row) in the brains of the clinically-affected mice from each 
treatment group. Haematoxylin (blue) was used as a nuclear counterstain. Scale bars, H&E panels 100 µm, all 
other panels 200 µm. (B) Immunoblot detection of high levels of prion disease-specific, relatively proteinase 
resistant PrPSc in representative brains of mice from each treatment group. Brain homogenates were treated in 
the presence ( + ) or absence (-) of proteinase K (PK) before electrophoresis. After PK treatment the samples 
present as a typical three-band pattern with molecular mass values between 20 to 30 kDa, representing the un-
glycosylated, mono-glycosylated, and di-glycosylated isomers of PrPSc (in order of increasing molecular mass). 
An uncropped image of the immunoblot is provided in Supplementary Fig. S1. (C) The magnitude of the prion 
disease-specific spongiform pathology (vacuolation) was scored on a scale of 0–5 in nine distinct grey matter 
regions (G1–G9) and three distinct white matter regions (W1–W3): G1, dorsal medulla; G2, cerebellar cortex; 
G3, superior colliculus; G4, hypothalamus; G5, thalamus; G6, hippocampus; G7, septum; G8, retrosplenial and 
adjacent motor cortex; G9, cingulate and adjacent motor cortex; W1, inferior and middle cerebellar peduncles; 
W2, decussation of superior cerebellar peduncles; W3, cerebellar peduncles. Closed circles, control-Ig; open 
circles, anti-αL + anti-α4; n = 7–8 mice/group. Not significantly different to mice treated with control-Ig,  
Two-way ANOVA.
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prion infections9,10,22,33,54. Thus, characterisation of the cellular and molecular mechanisms that prions utilise 
to establish infection within the spleen may reveal novel prophylactic or therapeutic targets for these currently 
untreatable and devastating diseases.
Materials and Methods
ethics statement. Ethical approvals for the in vivo mouse experiments were obtained from The Roslin 
Institute’s and University of Edinburgh’s ethics committees. All the experiments in this study were undertaken in 
accordance with the guidelines and regulations of the UK Home Office ‘Animals (scientific procedures) Act 1986’ 
and were performed under the authority of UK Home Office Project Licence PPL60/4325. Appropriate care was 
given to reduce harm and suffering, with anaesthesia was administered where necessary. At the end of the exper-
iments the mice were humanely culled by cervical dislocation.
Mice. Female C57BL/6 J mice were obtained from Charles River Laboratories (Charles River, Margate, UK) 
and housed under specific pathogen-free conditions with a 12:12 h light:dark cycle. Food and water were provided 
ad libitum. Mice were used in studies at 6–8 weeks old.
In vivo anti-integrin antibody treatment. Transient displacement of MZ B cells was achieved by IV 
injection with 100 µg each of rat anti-mouse LFA-1 mAb (CD11a, clone M17/4, IgG2aκ) and rat anti-mouse 
integrin α4 mAb (CD49d, clone R1-2, IgG2bκ) as described previously28–30. Where indicated some mice were 
injected with non-specific rat IgG2aκ (clone eBR2a) and rat IgG2bκ (clone eB149/10H5) as isotype controls. All 
these antibodies were purchased from ThermoFisher (Loughborough, UK).
flow cytometry. Single spleen cell suspensions were prepared and red blood cells lysed using red blood 
cell lysis buffer (Sigma, Poole, UK). Viable cells were counted and re-suspended in FACS buffer (PBS pH 7.4 
containing 0.1% BSA, 0.1% sodium azide and 0.02% EDTA). Non-specific immunoglobulin-binding was blocked 
using Mouse Seroblock FcR (Bio-Rad Laboratories Watford, UK) and cells subsequently immunostained with 
the following mAb purchased from BioLegend (London, UK): anti-mouse CD1d-PerCP/Cy5.5 (clone Ly-38); 
anti-mouse CD21/35-Pacific Blue (clone 7G6); anti-mouse CD45R:B220-APC (clone RA3-6B2). Relevant 
non-specific antibody isotypes were used as controls. Cells were analysed on a LSR Fortessa with DIVA software 
(BD Biosciences). Cells were gated on lymphocytes, doublets excluded and data analysed with FlowJo software 
(FlowJo, LLC, Ashland OR, USA).
intravenous prion infection. Mice were injected IV with 20 µl of a 0.1% (weight/volume) brain homoge-
nate prepared from mice terminally infected with ME7 scrapie prions (containing approximately 1 × 103 ID50 
units). The mice were then coded, and assessed blindly for the clinical signs of prion disease by independent 
husbandry technicians. Mice were culled at a standard clinical endpoint as described55. The clinical status of each 
mouse was confirmed by histopathological assessment of the prion disease-specific spongiform vacuolation in 
haematoxylin and eosin stained brain sections as described56.
immunohistochemistry. Snap-frozen spleens were embedded in optimal cryotomy temperature com-
pound and cryosectioned at 10 μm thickness. Sections were then immunostained using the following anti-
bodies: rat anti-mouse CD1d (clone 1B1; Bio-Rad Laboratories); rat anti-mouse CD21/35 (clone 7G6; BD 
Biosciences); anti-mouse CD45R:B220 (clone RA3-6B2); anti-mouse CD169 (MOMA-1; Bio-Rad Laboratories); 
Alexa Fluor 488-conjugated anti-mouse IgD (clone 11–26 c.2a; Biolegend); Alexa Fluor 594-conjugated goat 
anti-mouse IgM (µ chain; ThermoFisher); anti-mouse MARCO (clone ED31; Bio-Rad Laboratories); Armenian 
hamster anti-mouse SIGNR1 (clone 22D1; eBioscience). Where appropriate, binding of primary antibodies 
was detected using biotin- or fluorophore-conjugated goat anti-species specific secondary antibodies (Jackson 
Immunoresearch, West Grove, PA). The binding of biotinylated secondary antibodies was visualized using the 
Elite ABC/HRP kit (Vector Laboratories, Peterborough, UK) with diaminobenzidine (DAB) or NovaRed (Vector 
Laboratories) as substrates.
Spleens and brains from mice infected with prions were fixed in periodate-lysine-paraformaldehyde, pro-
cessed on an ASP300S automated tissue processor (Leica), embedded in paraffin wax and 5 µm sections prepared. 
Detection of disease-specific PrP (PrPd) was enhanced by hydrated autoclaving (15 min, 121 °C, hydration) fol-
lowed by immersion in formic acid (98%) for 5 min. PrP-specific polyclonal antiserum 1B357 was then used to 
detect PrP. Anti-glial fibrillary acidic protein (GFAP; DAKO, Ely, UK) was used to detect astrocytes. For the detec-
tion of microglia the sections were treated with Target Retrieval Solution (DAKO) and immunostained using 
anti-AIF-1/Iba1 (Wako Chemicals GmbH, Neuss, Germany). Appropriate species-specific biotin-conjugated 
secondary antibodies (Jackson ImmunoResearch Europe Ltd., Ely, UK) were subsequently used followed by 
HRP-conjugated to the avidin-biotin complex (ABC kit, Vector Laboratories, Peterborough, UK), and immuno-
labelling detected using diaminobenzidine (DAB; Sigma). Paraffin-embedded tissue immunoblot analysis was 
used to discriminate between prion disease-specific proteinase K-resistant PrPSc and cellular PrPC as described58.
For light microscopy, haematoxylin was used as a counterstain and sections imaged on a Ni.1 microscope 
(Nikon). For immunofluoresce the immunostained sections were mounted in fluorescent mounting medium 
(DakoCytomation, Glostrup, Denmark) and imaged using a Zeiss LSM710 confocal microscope with ZEN soft-
ware (Zeiss).
Western immunoblot analysis. Brains samples were homogenised in NP-40 lysis buffer (1% NP-40, 0.5% 
sodium deoxycholate, 150 mM NaCl, 50 mM Tris-HCL [pH 7.5]) at 10% weight/volume, and subsequently treated 
at 37 °C for 1 h with proteinase K (20 µg/ml). Samples were then separated by electrophoresis and electroblotted 
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onto polyvinylidene difluoride membranes as described previously42. PrP was detected using anti-mouse PrP 
mAb (clone 7A12; Yin et al., 2007), followed by HRP-conjugated anti-mouse antibody (Jackson Immunoresearch, 
Ely, UK) and visualised with BM Chemiluminescent substrate kit (Roche, Burgess Hill, UK). An uncropped 
image of the immunoblot is provided in Supplementary Fig. S1.
Statistical Analyses. Data are presented as mean ± SEM. Significant differences between groups were deter-
mined by Student’s t-test, unless indicated otherwise otherwise. Values of P < 0.05 were accepted as significant.
Data availability
All relevant data are presented within the paper.
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